Cargando…
Development and internal validation of a predictive risk model for anxiety after completion of treatment for early stage breast cancer
OBJECTIVE: To develop a predictive risk model (PRM) for patient-reported anxiety after treatment completion for early stage breast cancer suitable for use in practice and underpinned by advances in data science and risk prediction. METHODS: Secondary analysis of a prospective survey of > 800 wome...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718350/ https://www.ncbi.nlm.nih.gov/pubmed/33275165 http://dx.doi.org/10.1186/s41687-020-00267-w |
_version_ | 1783619487193366528 |
---|---|
author | Harris, Jenny Purssell, Edward Cornelius, Victoria Ream, Emma Jones, Anne Armes, Jo |
author_facet | Harris, Jenny Purssell, Edward Cornelius, Victoria Ream, Emma Jones, Anne Armes, Jo |
author_sort | Harris, Jenny |
collection | PubMed |
description | OBJECTIVE: To develop a predictive risk model (PRM) for patient-reported anxiety after treatment completion for early stage breast cancer suitable for use in practice and underpinned by advances in data science and risk prediction. METHODS: Secondary analysis of a prospective survey of > 800 women at the end of treatment and again 6 months later using patient reported outcome (PRO) the hospital anxiety and depression scale-anxiety (HADS-A) and > 20 candidate predictors. Multiple imputation using chained equations (for missing data) and least absolute shrinkage and selection operator (LASSO) were used to select predictors. Final multivariable linear model performance was assessed (R(2)) and bootstrapped for internal validation. RESULTS: Five predictors of anxiety selected by LASSO were HADS-A (Beta 0.73; 95% CI 0.681, 0.785); HAD-depression (Beta 0.095; 95% CI 0.020, 0.182) and having caring responsibilities (Beta 0.488; 95% CI 0.084, 0.866) increased risk, whereas being older (Beta − 0.010; 95% CI -0.028, 0.004) and owning a home (Beta 0.432; 95% CI -0.954, 0.078) reduced the risk. The final model explained 60% of variance and bias was low (− 0.006 to 0.002). CONCLUSIONS: Different modelling approaches are needed to predict rather than explain patient reported outcomes. We developed a parsimonious and pragmatic PRM. External validation is required prior to translation to digital tool and evaluation of clinical implementation. The routine use of PROs and data driven PRM in practice provides a new opportunity to target supportive care and specialist interventions for cancer patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41687-020-00267-w. |
format | Online Article Text |
id | pubmed-7718350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-77183502020-12-07 Development and internal validation of a predictive risk model for anxiety after completion of treatment for early stage breast cancer Harris, Jenny Purssell, Edward Cornelius, Victoria Ream, Emma Jones, Anne Armes, Jo J Patient Rep Outcomes Research OBJECTIVE: To develop a predictive risk model (PRM) for patient-reported anxiety after treatment completion for early stage breast cancer suitable for use in practice and underpinned by advances in data science and risk prediction. METHODS: Secondary analysis of a prospective survey of > 800 women at the end of treatment and again 6 months later using patient reported outcome (PRO) the hospital anxiety and depression scale-anxiety (HADS-A) and > 20 candidate predictors. Multiple imputation using chained equations (for missing data) and least absolute shrinkage and selection operator (LASSO) were used to select predictors. Final multivariable linear model performance was assessed (R(2)) and bootstrapped for internal validation. RESULTS: Five predictors of anxiety selected by LASSO were HADS-A (Beta 0.73; 95% CI 0.681, 0.785); HAD-depression (Beta 0.095; 95% CI 0.020, 0.182) and having caring responsibilities (Beta 0.488; 95% CI 0.084, 0.866) increased risk, whereas being older (Beta − 0.010; 95% CI -0.028, 0.004) and owning a home (Beta 0.432; 95% CI -0.954, 0.078) reduced the risk. The final model explained 60% of variance and bias was low (− 0.006 to 0.002). CONCLUSIONS: Different modelling approaches are needed to predict rather than explain patient reported outcomes. We developed a parsimonious and pragmatic PRM. External validation is required prior to translation to digital tool and evaluation of clinical implementation. The routine use of PROs and data driven PRM in practice provides a new opportunity to target supportive care and specialist interventions for cancer patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41687-020-00267-w. Springer International Publishing 2020-12-04 /pmc/articles/PMC7718350/ /pubmed/33275165 http://dx.doi.org/10.1186/s41687-020-00267-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Harris, Jenny Purssell, Edward Cornelius, Victoria Ream, Emma Jones, Anne Armes, Jo Development and internal validation of a predictive risk model for anxiety after completion of treatment for early stage breast cancer |
title | Development and internal validation of a predictive risk model for anxiety after completion of treatment for early stage breast cancer |
title_full | Development and internal validation of a predictive risk model for anxiety after completion of treatment for early stage breast cancer |
title_fullStr | Development and internal validation of a predictive risk model for anxiety after completion of treatment for early stage breast cancer |
title_full_unstemmed | Development and internal validation of a predictive risk model for anxiety after completion of treatment for early stage breast cancer |
title_short | Development and internal validation of a predictive risk model for anxiety after completion of treatment for early stage breast cancer |
title_sort | development and internal validation of a predictive risk model for anxiety after completion of treatment for early stage breast cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718350/ https://www.ncbi.nlm.nih.gov/pubmed/33275165 http://dx.doi.org/10.1186/s41687-020-00267-w |
work_keys_str_mv | AT harrisjenny developmentandinternalvalidationofapredictiveriskmodelforanxietyaftercompletionoftreatmentforearlystagebreastcancer AT pursselledward developmentandinternalvalidationofapredictiveriskmodelforanxietyaftercompletionoftreatmentforearlystagebreastcancer AT corneliusvictoria developmentandinternalvalidationofapredictiveriskmodelforanxietyaftercompletionoftreatmentforearlystagebreastcancer AT reamemma developmentandinternalvalidationofapredictiveriskmodelforanxietyaftercompletionoftreatmentforearlystagebreastcancer AT jonesanne developmentandinternalvalidationofapredictiveriskmodelforanxietyaftercompletionoftreatmentforearlystagebreastcancer AT armesjo developmentandinternalvalidationofapredictiveriskmodelforanxietyaftercompletionoftreatmentforearlystagebreastcancer |